Eikon Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-01-09. It has amended it 1 time. It filed its final prospectus on 2026-02-05, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Select Market, or Nasdaq, under the trading symbol “EIKN.”From the 424B4 filed 2026-02-05
Shares offered
This is an initial public offering of shares of common stock of Eikon Therapeutics, Inc. We are offering 21,177,600 shares of our common stock.From the 424B4 filed 2026-02-05
Offering price
The initial public offering price is $18.00 per share.From the 424B4 filed 2026-02-05
Use of proceeds
We intend to use the net proceeds to us from this offering to advance the clinical development of EIK1001, our most advanced product candidate, through (i) the ongoing Phase 2 portion of our Phase 2/3 registrational trial in advanced melanoma, (ii) completion of the full data readout of our ongoing Phase 2 trial in NSCLC, and (iii) advancement of our Phase 2/3 registrational trial in NSCLC; to advance the clinical development of EIK1003 through completion of our Phase 1/2 clinical trial, including the combination cohorts and dose optimization; to advance the clinical development of EIK1004 through completion of Part 1 of our Phase 1/2 clinical trial and initiation of Part 2 thereof; to…From the 424B4 filed 2026-02-05
Net loss or income
For the nine months ended September 30, 2025 and the years ended December 31, 2024 and 2023, we reported a net loss of $244.6 million, $243.8 million, and $242.0 million, respectively.From the S-1/A filed 2026-01-28
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-01-09 | Registration statement filed | S-1 |
| 2026-01-28 | Registration statement amended | S-1/A |
| 2026-02-05 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Eikon Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.